Pharmaceutical company Upsher-Smith Laboratories LLC revealed on Friday the launch of an exclusive agreement with a pharmaceutical partner to market and distribute a group of six ophthalmic and otic ANDA products, with combined annual sales of more than USD1.6bn (IQVIA, 12 months ending March 2018).

This partnership collaboration is part of its company-wide effort to grow its generics pipeline as well as expand its strategic relationships within the pharmaceutical industry.

The agreement allows Upsher-Smith to register the products with the US Food and Drug Administration (FDA) as well as market and distribute them under its own label in the US upon US FDA approval.

In conjunction, the partner company will develop and manufacture the products exclusively for Upsher-Smith.

Financial terms related to the deal have not been disclosed by the companies.